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In 1911 and long before the availability of antiallergic drugs,Leonard Noon demonstrated that prophylactic subcutane-
ous inoculation with a grass pollen extract was effective in
suppressing immediate conjunctival sensitivity to grass pol-
len.1 Noon’s coworker, John Freeman, continued to practice
immunotherapy and in 1930 published the first rush immu-
notherapy protocol.2 William Frankland, a colleague of Free-
man, performed the first controlled clinical trial of grass
pollen immunotherapy in 1954.3 He used a whole grass
pollen extract that was compared with its partially purified
proteins, the corresponding ultrafiltrate that contained no protein
and a phenol-containing diluent. Both the whole extract and the
purified grass pollen proteins were effective compared with the
ultrafiltrate and the diluent control alone (Fig. 1). Frankland’s
study established a firm scientific foundation for the practice of
allergen immunotherapy. Noon, Freeman, and Frankland were
all physicians at St. Mary’s Hospital, Paddington, now affiliated
to Imperial College London, United Kingdom. Frankland in his
99th year continues to practice and play a major role in the
allergy community; much admired and respected by his col-
leagues, he represents our centenary link with the origins of the
practice of immunotherapy (Fig. 2).
Major advances in allergen immunotherapy have re-
sulted from parallel studies performed in the United States.
Lowell and Franklin in 1964 were the first to clearly demon-
strate that a single allergen (ragweed) in a multiallergen
mixture was effective in reducing seasonal allergic symp-
toms.4 Philip Norman and Larry Lichtenstein in 1978 con-
vincingly demonstrated the allergen-specificity of ragweed
immunotherapy in patients with dual sensitivity to ragweed
and grass pollen.5 Johnstone first highlighted the possibility
that immunotherapy in children might confer protection
against development of asthma,6 a concept supported by the
more recent Preventive Allergy Treatment (PAT) study that
identified a 2–3 fold risk reduction for developing asthma
after 3 years treatment in children with seasonal pollinosis,
protection that persisted for a further 7 years after discontin-
uation of immunotherapy.7 Hunt and colleagues8 demon-
strated the efficacy of purified venom over whole insect body
extract and placebo in patients with anaphylaxis to the stings
of hymenoptera. Studies9 have confirmed the dose-depen-
dency of allergen immunotherapy whereas the long-term
benefits of allergen immunotherapy, with persistence of effi-
cacy for several years after discontinuation10 have been
illustrated for both venom11 and grass pollen immunotherapy,
the latter both for subcutaneous and sublingual routes of
therapy.12
Our increasing knowledge of the mechanisms of im-
munotherapy has informed both novel approaches and the
development of putative biomarkers that might predict the
clinical response to immunotherapy. Prausnitz and Kustner13
published in 1921 that a serum factor (‘reagin’) could transfer
immediate allergen sensitivity as shown by skin testing was
followed Robert Cooke’s observation in 1935 that serum
obtained after pollen immunotherapy could confer ‘immunity
and hypersensitivity.’14 These seminal observations long pre-
ceded the discovery of IgE antibody as reagin by the Ishiza-
kas,15 Johansson and Bennich,16 and the concept of IgG
‘blocking antibodies.’17 The suppressive effect of ragweed
immunotherapy on nasal eosinophils as a local marker of
allergic inflammation was shown by Creticos in 1984,18
whereas Passalacqua and Canonica similarly demonstrated
decreased local eosinophilia and adhesion molecule expres-
sion during mite sublingual immunotherapy.19 Warner in
197820 and Rak21 in 1991 observed decreases in allergen-
induced late asthmatic responses and associated bronchial
inflammation, respectively, in children and adults. A link
between altered T-cell responses and immunotherapy was
first shown by Rocklin22 whereas the critical role of regula-
tory T cells and IL-10 was highlighted by Akdis and col-
leagues.23 The concept of immune deviation of allergen-
specific TH2 responses in favor of TH1 responses in both the
periphery and in target organs has developed in parallel.24–26
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FIGURE 1. Table II shows the results of the first immuno-
therapy controlled trial, as published in: Frankland AW,
Augustin R. Prophylaxis of summer hay-fever and asthma: a
controlled trial comparing crude grass-pollen extracts with
the isolated main protein component, The Lancet, May 24,
1954.
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It is paradoxical that 100 years on we continue to use
conventional high-dose subcutaneous injection immunother-
apy with allergen extracts as gold standard therapy. A key
question remains whether either B cell and/or T cell epitopes
expressed by allergens are necessary singly or together for
successful immunotherapy. Whether T-cell focused therapies
alone are sufficient is currently being tested in the context of
T-cell peptide immunotherapy.27,28 Other novel approaches
such as the focus on adjuvants in combination with aller-
gens,29,30 alternative routes of administration (sublingual,31
transdermal,32 intranodal33) and the use of recombinant aller-
gens and their hypo-allergenic variants34 are all currently
being tested in phase II–III trials.
These novel strategies will hopefully augment efficacy
while improving the safety of immunotherapy, thereby mak-
ing immunotherapy more broadly available to allergy suffer-
ers, including patients with more severe allergic asthma.
Further confirmation that immunotherapy has potential to
induce remission and prevent progression of allergic disease
should attract earlier interventions in children and young
adults who are the group who may potentially benefit most
from this disease-modifying treatment.
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